We’re excited to share that our Epilepsy Meds mobile app, developed in collaboration with Desitin Pharma and medical content partners ChangeMed, has been shortlisted as a finalist in the PM Society Digital Awards 2025.
The app is nominated in the HCP Education, Training & Support category, which recognises digital initiatives that improve understanding and clinical decision-making amongst healthcare professionals.
Designed for epilepsy specialists, nurses, and pharmacists, Epilepsy Meds provides fast, ABPI-compliant access to detailed information about anti-seizure medications — helping HCPs filter products by formulation, excipients, and suitability for different patient needs. It’s now being used across the NHS to support confident, patient-centred prescribing decisions.
This recognition is a testament to the shared vision between Desitin, ChangeMed and Genetic Digital — combining clinical insight, user-centred design, and digital innovation to make a meaningful difference in care delivery.
Thank you to the PM Society for the recognition. We’re looking forward to the presentation stage and to celebrating with other finalists at the awards ceremony this September!
